Amylin signs weight-loss drug deal with Takeda
November 2, 2009
Amylin Pharmaceuticals Inc. could potentially receive more than $1 billion from a partnership with Japan''s Takeda Pharmaceutical Co. on potential weight-loss treatments, reports the Associated Press. Amylin, which is based in San Diego, said it will receive $75 million upfront from Takeda and said future payments for development and achieving commercial milestones could top $1 billion. The deal includes two potential weight-loss treatments, a pramlintide-metreleptin combination and davalintide. Both potential drugs are in midstage, or Phase II, clinical development. The deal also includes additional compounds from both companies research programs. Aside from milestone payments, Amylin is also eligible for royalties on global sales.